PubRank

Pasi A Jänne

Author PubWeight™ 505.05‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004 61.56
2 Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010 36.78
3 MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007 32.68
4 EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005 26.35
5 Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013 14.78
6 Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 2012 11.69
7 Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005 9.95
8 First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008 9.43
9 EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 2008 9.29
10 An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays. Cancer Res 2004 8.86
11 Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012 8.64
12 LKB1 modulates lung cancer differentiation and metastasis. Nature 2007 7.80
13 Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 2010 7.78
14 Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 2009 7.05
15 Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. Nat Med 2006 6.96
16 Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res 2005 6.93
17 Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 2008 6.91
18 Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med 2012 6.77
19 ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci U S A 2005 6.35
20 Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med 2010 6.28
21 Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med 2005 6.04
22 Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J Clin Invest 2006 5.73
23 Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol 2009 5.70
24 PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res 2007 5.45
25 The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell 2006 5.34
26 Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255. Cancer Res 2004 5.23
27 Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. Cancer Cell 2007 4.85
28 A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res 2010 4.51
29 Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med 2011 4.51
30 A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res 2011 4.22
31 Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma. Int J Radiat Oncol Biol Phys 2006 4.22
32 Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. J Natl Cancer Inst 2005 4.19
33 Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res 2006 4.11
34 Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res 2009 3.65
35 Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol 2007 3.50
36 Circumventing cancer drug resistance in the era of personalized medicine. Cancer Discov 2012 3.25
37 A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature 2012 3.24
38 The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat Med 2013 3.20
39 The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. Cancer Res 2010 3.16
40 Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. J Clin Oncol 2010 3.15
41 The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer 2010 3.03
42 Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol 2006 2.82
43 Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression. Cancer Res 2005 2.49
44 Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial. J Clin Oncol 2007 2.48
45 Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors. Cancer Discov 2012 2.47
46 Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models. Cancer Res 2007 2.45
47 Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer. Clin Cancer Res 2009 2.35
48 Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers. Clin Cancer Res 2008 2.28
49 New targetable oncogenes in non-small-cell lung cancer. J Clin Oncol 2013 2.25
50 Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene. Cancer Res 2010 2.20
51 Response and acquired resistance to everolimus in anaplastic thyroid cancer. N Engl J Med 2014 2.09
52 Integration of molecular profiling into the lung cancer clinic. Clin Cancer Res 2009 2.06
53 Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib. Clin Cancer Res 2008 2.00
54 New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy. AJR Am J Roentgenol 2010 1.95
55 EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH, CISH, and immunohistochemistry. Am J Clin Pathol 2010 1.86
56 Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial. J Clin Oncol 2008 1.79
57 A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. Clin Cancer Res 2009 1.79
58 Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing. Oncologist 2007 1.75
59 A new device for rapid isolation by size and characterization of rare circulating tumor cells. Anticancer Res 2011 1.74
60 Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors. Cancer Res 2011 1.67
61 Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway. Cancer Res 2012 1.66
62 Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy. J Clin Oncol 2013 1.66
63 Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer. J Clin Oncol 2011 1.63
64 Role of ERK-BIM and STAT3-survivin signaling pathways in ALK inhibitor-induced apoptosis in EML4-ALK-positive lung cancer. Clin Cancer Res 2011 1.62
65 Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers. Cancer Discov 2011 1.57
66 EGFR-mutated oncogene-addicted non-small cell lung cancer: current trends and future prospects. Cancer Treat Rev 2011 1.57
67 Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. J Clin Oncol 2006 1.56
68 The introduction of systematic genomic testing for patients with non-small-cell lung cancer. J Thorac Oncol 2012 1.53
69 CT tumor volume measurement in advanced non-small-cell lung cancer: Performance characteristics of an emerging clinical tool. Acad Radiol 2010 1.51
70 Discordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumors and lymph node metastasis in non-small cell lung cancer. J Thorac Oncol 2009 1.50
71 Epidermal growth factor receptor inhibition in lung cancer: status 2012. J Thorac Oncol 2013 1.50
72 EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma. Clin Cancer Res 2011 1.50
73 Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. Clin Cancer Res 2009 1.49
74 Gemcitabine-induced radiation recall. Int J Radiat Oncol Biol Phys 2002 1.49
75 Single-agent and combination therapeutic strategies to inhibit hepatocyte growth factor/MET signaling in cancer. Clin Cancer Res 2008 1.48
76 Epidermal growth factor receptor mutations in patients with non-small cell lung cancer. Cancer Res 2005 1.47
77 High risk of brain metastases in surgically staged IIIA non-small-cell lung cancer patients treated with surgery, chemotherapy, and radiation. J Clin Oncol 2005 1.44
78 Epidermal growth factor receptor mutation testing in the care of lung cancer patients. Clin Cancer Res 2006 1.40
79 Induction docetaxel and carboplatin followed by weekly docetaxel and carboplatin with concurrent radiotherapy, then surgery in stage III non-small cell lung cancer: a Phase I study. Clin Cancer Res 2003 1.38
80 Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol 2012 1.37
81 Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions. J Thorac Oncol 2013 1.36
82 Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer. Clin Cancer Res 2013 1.36
83 Selecting patients for epidermal growth factor receptor inhibitor treatment: A FISH story or a tale of mutations? J Clin Oncol 2005 1.35
84 Crizotinib for ALK-rearranged non-small cell lung cancer: a new targeted therapy for a new target. Clin Cancer Res 2012 1.34
85 Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial. J Thorac Oncol 2010 1.34
86 Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitor. Angew Chem Int Ed Engl 2013 1.34
87 EGFR mutations are detected comparably in cytologic and surgical pathology specimens of nonsmall cell lung cancer. Cancer 2009 1.28
88 Combined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers codriven by mutant EGFR containing T790M and MET. Cancer Res 2012 1.27
89 Coamplification at lower denaturation temperature-PCR increases mutation-detection selectivity of TaqMan-based real-time PCR. Clin Chem 2009 1.24
90 Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma. J Clin Oncol 2006 1.23
91 Drug discovery: inhibitors that activate. Nature 2010 1.22
92 Phase I study of U3-1287, a fully human anti-HER3 monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res 2013 1.21
93 ROS1 immunohistochemistry for detection of ROS1-rearranged lung adenocarcinomas. Am J Surg Pathol 2013 1.20
94 Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplification. Cancer Sci 2009 1.18
95 A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib. Cancer 2014 1.15
96 RECIST 1.1 in NSCLC patients with EGFR mutations treated with EGFR tyrosine kinase inhibitors: comparison with RECIST 1.0. AJR Am J Roentgenol 2013 1.15
97 Lung adenocarcinoma with EGFR amplification has distinct clinicopathologic and molecular features in never-smokers. Cancer Res 2009 1.13
98 Responsiveness to cetuximab without mutations in EGFR. N Engl J Med 2005 1.12
99 Sensitivity of breast cancer cell lines to the novel insulin-like growth factor-1 receptor (IGF-1R) inhibitor NVP-AEW541 is dependent on the level of IRS-1 expression. Cancer Lett 2009 1.07
100 TAK-701, a humanized monoclonal antibody to hepatocyte growth factor, reverses gefitinib resistance induced by tumor-derived HGF in non-small cell lung cancer with an EGFR mutation. Mol Cancer Ther 2010 1.07
101 Inhibition of the met receptor in mesothelioma. Clin Cancer Res 2005 1.05
102 Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma. Cancer 2008 1.05
103 Fulminant hepatic failure secondary to erlotinib. Clin Gastroenterol Hepatol 2007 1.04
104 Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents. Clin Cancer Res 2006 1.03
105 A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307. J Thorac Oncol 2010 1.02
106 New strategies for treatment of ALK-rearranged non-small cell lung cancers. Clin Cancer Res 2011 1.01
107 Rationale for a phase I trial of erlotinib and the mammalian target of rapamycin inhibitor everolimus (RAD001) for patients with relapsed non small cell lung cancer. Clin Cancer Res 2007 1.01
108 Tumor volume decrease at 8 weeks is associated with longer survival in EGFR-mutant advanced non-small-cell lung cancer patients treated with EGFR TKI. J Thorac Oncol 2013 1.01
109 Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization. Cancer Res 2013 1.00
110 Outcome of patients with pulmonary carcinoid tumors receiving chemotherapy or chemoradiotherapy. Lung Cancer 2004 1.00
111 Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors. Lung Cancer 2012 1.00
112 Volumetric tumor growth in advanced non-small cell lung cancer patients with EGFR mutations during EGFR-tyrosine kinase inhibitor therapy: developing criteria to continue therapy beyond RECIST progression. Cancer 2013 0.98
113 Using tandem mass spectrometry in targeted mode to identify activators of class IA PI3K in cancer. Cancer Res 2011 0.98
114 The road to resistance: EGFR mutation and cetuximab. Nat Med 2012 0.98
115 A pooled exploratory analysis of the effect of tumor size and KRAS mutations on survival benefit from adjuvant platinum-based chemotherapy in node-negative non-small cell lung cancer. J Thorac Oncol 2012 0.97
116 Are there any ethnic differences in molecular predictors of erlotinib efficacy in advanced non-small cell lung cancer? Clin Cancer Res 2008 0.97
117 s-RT-MELT for rapid mutation scanning using enzymatic selection and real time DNA-melting: new potential for multiplex genetic analysis. Nucleic Acids Res 2007 0.97
118 Imaging of lung cancer in the era of molecular medicine. Acad Radiol 2011 0.97
119 ROS1 rearrangements in lung cancer: a new genomic subset of lung adenocarcinoma. J Clin Oncol 2012 0.95
120 Bronchioloalveolar carcinoma: a review of the epidemiology, pathology, and treatment. Semin Respir Crit Care Med 2005 0.94
121 Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification. Clin Cancer Res 2009 0.93
122 Zeroing in on ROS1 rearrangements in non-small cell lung cancer. Clin Cancer Res 2012 0.91
123 Basic treatment considerations using chemotherapy for patients with small cell lung cancer. Hematol Oncol Clin North Am 2004 0.90
124 c-Met, epidermal growth factor receptor, and insulin-like growth factor-1 receptor are important for growth in uveal melanoma and independently contribute to migration and metastatic potential. Melanoma Res 2012 0.89
125 Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer. J Thorac Oncol 2015 0.89
126 Outcomes of patients with stage III nonsmall cell lung cancer treated with chemotherapy and radiation with and without surgery. Cancer 2009 0.87
127 Biotinylated probe isolation of targeted gene region improves detection of T790M epidermal growth factor receptor mutation via peptide nucleic acid-enriched real-time PCR. Clin Chem 2011 0.86
128 Discovery of selective irreversible inhibitors for EGFR-T790M. Bioorg Med Chem Lett 2010 0.86
129 Rationale for a phase II trial of pertuzumab, a HER-2 dimerization inhibitor, in patients with non-small cell lung cancer. Clin Cancer Res 2006 0.85
130 Management of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced non-small cell lung cancer. Cancer 2014 0.84
131 Power in numbers: meta-analysis to identify inhibitor-sensitive tumor genotypes. Clin Cancer Res 2013 0.84
132 A phase II study of induction chemotherapy followed by thoracic radiotherapy and erlotinib in poor-risk stage III non-small-cell lung cancer: results of CALGB 30605 (Alliance)/RTOG 0972 (NRG). J Thorac Oncol 2015 0.83
133 Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma: outcomes of an expanded access program. Lung Cancer 2006 0.83
134 Influence of radiotherapy technique and dose on patterns of failure for mesothelioma patients after extrapleural pneumonectomy. Int J Radiat Oncol Biol Phys 2007 0.82
135 Clinical Implications of Variant ALK FISH Rearrangement Patterns. J Thorac Oncol 2015 0.82
136 A sensitive high-throughput method to detect activating mutations of Jak2 in peripheral-blood samples. Blood 2006 0.80
137 Factors predicting response to EGFR tyrosine kinase inhibitors. Semin Respir Crit Care Med 2005 0.80
138 Discovery of 3,5-Diamino-1,2,4-triazole Ureas as Potent Anaplastic Lymphoma Kinase Inhibitors. ACS Med Chem Lett 2011 0.80
139 Translational medicine: Primed for resistance. Nature 2012 0.79
140 An amino-indazole scaffold with spectrum selective kinase inhibition of FLT3, PDGFRα and kit. Bioorg Med Chem Lett 2012 0.78
141 Gefitinib for epidermal growth factor receptor mutant lung cancers: searching for a weapon of mass destruction. J Clin Oncol 2006 0.78
142 A severe photosensitivity dermatitis caused by crizotinib. J Thorac Oncol 2014 0.77
143 Treatment of peritoneal mesothelioma in pediatric patients. Pediatr Blood Cancer 2009 0.77
144 Prospective study of the airways and pulmonary parenchyma of patients at risk for a second lung cancer. Clin Cancer Res 2003 0.76
145 KRAS wild-type lung cancer: a moving target in an era of genotype migration. J Clin Oncol 2012 0.76
146 Monitoring cancer through the blood. Cancer 2014 0.75
147 Gefitinib first or gefitinib second: is timing everything in the treatment of EGFR mutant non-small cell lung cancer? Am J Respir Crit Care Med 2008 0.75
148 Does erlotinib improve symptoms in patients with lung cancer? Nat Clin Pract Oncol 2007 0.75
149 KRAS mutation analysis helps to differentiate between pulmonary metastasis from colon adenocarcinoma in situ and primary lung adenocarcinoma. J Thorac Oncol 2011 0.75
150 Histology... For want of anything better? Oncology (Williston Park) 2009 0.75